BD FACSAria II

描述（由申请人提供）：我们正在申请资金用于购买最先进的荧光激活细胞分选仪（FACS），BD Biosciences FACSAria II，以支持斯坦福大学医学院新成立的干细胞生物学和再生医学研究所（ISCBRM）的研究项目。ISCBRM正在迅速扩大，在过去两年中增加了三名新的教师，2009年又增加了两名。流式细胞术是ISCBRM研究各个方面的关键平台技术，包括从正常组织中鉴定、分离和表征高度纯化的干细胞和祖细胞亚群，以及从各种恶性组织中鉴定、分离和表征癌症干细胞。由于在我们的流式细胞仪分选中分离的干细胞群体非常罕见，每次分选通常需要至少两到四个小时。此外，大多数实验需要两次连续分选运行以充分去除污染细胞。因此，单个实验可能需要4-8小时的FACS分选时间。ISCBRM的人员配备增加，加上所有教职员工都需要长时间对感兴趣的细胞进行流式细胞仪分选，最近导致了流式细胞术访问方面的瓶颈，这严重阻碍了科学进步。进一步强调我们需要额外的FACS的另一个考虑是，ISCBRM的许多项目使用在短时间内收到的人类癌症组织，通常在必须执行活细胞分选之前不超过几个小时到1-2天。这种情况需要流式细胞术能力在时间安排和可用性方面具有足够的灵活性，以便在短时间内容纳样品。我们目前的流式细胞仪设备的密集使用使得在短时间内处理样本几乎是不可能的，并且在许多情况下浪费了珍贵和稀有的临床样本。以下提案列出了需要额外FACS访问的教职员工，并描述了他们实验室中需要大量FACS分选时间的项目。我们特别要求BD Biosciences FACSAria II，因为本文所述的每个项目都需要多参数分选。总之，我们迫切需要购买FACSAria II，以缓解我们目前的流式细胞术访问瓶颈，从而加快我们在干细胞研究方面的进展，并提供足够的调度灵活性，以便能够在短时间内处理极具价值的临床样本。

DESCRIPTION (provided by applicant): We are requesting funds for the purchase of a state-of-the art fluorescence activated cell sorter (FACS), the BD Biosciences FACSAria II, to support research projects in the newly established Institute of Stem Cell Biology and Regenerative Medicine (ISCBRM) at Stanford University School of Medicine. The ISCBRM is expanding rapidly, with three new faculty members added in the last two years, and another two being added in 2009. FACS is the key platform technology for all aspects of the research at ISCBRM, including the identification, isolation, and characterization of highly purified subsets of stem and progenitor cells from normal tissues, and cancer stem cells from a wide variety of malignant tissues. Due to the rarity of the stem cell populations isolated in our FACS sorts, each sort routinely requires a minimum of two to four hours. In addition, most experiments require two sequential sorting runs to adequately remove contaminating cells. So individual experiments can require 4-8 hours of FACS sorting time. The increased staffing at ISCBRM, combined with the fact that all faculty members require long hours of FACS sorting of their cells of interest, has recently led to a bottleneck in terms of flow cytometry access, and this is significantly impeding scientific progress. Another consideration that further underscores our need for an additional FACS is that many projects at ISCBRM use human cancer tissues which are received at short notice, often with no more than a few hours to 1-2 days before sorting of the live cells must be executed. This situation requires a flow cytometry capacity with sufficient flexibility in scheduling and availability to accommodate samples at short notice. The intensive use of our current FACS facility makes it almost impossible to handle samples at short notice, and there have been many occasions when precious and rare clinical samples have been wasted. The following proposal lists the faculty members who need additional FACS access, and describes the projects in their labs that require extensive FACS sorting time. We are specifically requesting a BD Biosciences FACSAria II because each of the projects described herein requires multi-parameter sorting. In summary we have a pressing need to purchase a FACSAria II to relieve our current flow cytometry access bottleneck and thereby accelerate our progress in stem cell research, and to provide sufficient scheduling flexibility to be able to handle extremely valuable clinical samples at short notice.